2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

By sjmartinez • October 30, 2024

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Epub ahead of print. PMID: 39471458.

Tags: covid-19, guideline, Infectious Diseases, pemivibart, Pre-exposure prophylaxis, Publications, SARS-CoV-2

Related Posts

Access to HIV treatment during community-wide flooding: Experiences of people living with HIV and health care workers in Malawi, a mixed methods study

Mphande M, Paneno R, Robson I, Phiri K, Cornell M, van Oosterhout JJ, Eisenman DP, Njala J, Phiri S, Dovel K. Access to HIV treatment[...]

Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research

Gianella S, Lauring A, Paredes R, Croda J, Andes D, Uhlemann AC, Chew K, Stephenson KE, Lewnard JA, John ARO, Leung DT, Clancy CJ, Chu[...]

Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans

Zhou X, Hilk A, Solis NV, Scott N, Zajac C, Filler SG, Selmecki A. Recurrent mutations in the stress regulator Cap1 reveal a trade-off between[...]